지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.10
- 수록면
- 181 - 191 (11page)
이용수
초록· 키워드
오류제보하기
Background：Duloxetine is an antidepressant that effects a serotonergic and noradrenergic neurotransmitter, and a useful agent in the treatment of the patients with depressive or anxiety or somatoform disorders. According to the recently reported study results, combination therapy with other antidepressants in the treatment of patients with major depressive disorder did not show a superior efficacy but might have a greater risk of producing adverse events. But, combination strategy is still most commonly used to make clinical improvement in clinical practice.
Objectives：The purpose of this study was to compare duloxetine monotherapy to combination therapy with other antidepressants in patients with depressive, anxiety or somatoform disorders.
Methods：An 8-week, naturalistic, retrospective, multi-center study in outpatients with depressive, anxiety or somatoform disorders was undertaken. A total of 174 patients that had been taken with duloxetine were enrolled in this study from July, 2009 to June, 2014 through 3 centers. We compared the mean changes of the Clinical Global Impression Scale-Severity(CGI-S) as primary efficacy measure and the discontinuation rate and adverse effect as secondary measures between duloxetine monotherapy group(n=71) and combination therapy with other antidepressants group (n=103) at baseline, 1, 2, 4, 8 week.
Results：There were no significant differences across the demographic characteristics between duloxetine monotherapy group and combination therapy group. There was a statistically greater improvement on the CGI-S in the combination group compared with the monotherapy group in patients with depressive(p=0.04) and anxiety disorders(p=0.02). There were no significant difference in the discontinuation rate and adverse event between duloxetine monotherapy group and combination therapy group.
Conclusion：Despite the limitation of our retrospective study, this results suggest that duloxetine combination therapy with other antidepressants compared to monotherapy would have a superior efficacy and similar tolerability in the treatment of patients with depressive and anxiety disorders. Adequately powered, well-controlled clinical trials are strongly warranted to confirm our findings due to methodological shortcomings.
Objectives：The purpose of this study was to compare duloxetine monotherapy to combination therapy with other antidepressants in patients with depressive, anxiety or somatoform disorders.
Methods：An 8-week, naturalistic, retrospective, multi-center study in outpatients with depressive, anxiety or somatoform disorders was undertaken. A total of 174 patients that had been taken with duloxetine were enrolled in this study from July, 2009 to June, 2014 through 3 centers. We compared the mean changes of the Clinical Global Impression Scale-Severity(CGI-S) as primary efficacy measure and the discontinuation rate and adverse effect as secondary measures between duloxetine monotherapy group(n=71) and combination therapy with other antidepressants group (n=103) at baseline, 1, 2, 4, 8 week.
Results：There were no significant differences across the demographic characteristics between duloxetine monotherapy group and combination therapy group. There was a statistically greater improvement on the CGI-S in the combination group compared with the monotherapy group in patients with depressive(p=0.04) and anxiety disorders(p=0.02). There were no significant difference in the discontinuation rate and adverse event between duloxetine monotherapy group and combination therapy group.
Conclusion：Despite the limitation of our retrospective study, this results suggest that duloxetine combination therapy with other antidepressants compared to monotherapy would have a superior efficacy and similar tolerability in the treatment of patients with depressive and anxiety disorders. Adequately powered, well-controlled clinical trials are strongly warranted to confirm our findings due to methodological shortcomings.
목차
서론
대상 및 방법
결과
고찰
참고문헌
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Effectiveness of Duloxetine Monotherapy Compared to Combination Therapy with Other Antidepressants in Patients with Major Depressive Disorder: A Short-Term, Retrospective Study
PSYCHIATRY INVESTIGATION
2016 .01
-
한국형 우울장애 약물치료 알고리듬 2017(I) : 정신병적 양상이 없는 주요우울장애
우울조울병
2017 .01
-
우울증 환자에서 항우울제 단독요법과 항정신병제와 항우울제의 병용요법의 자살위험비교: 정신건강의학 공통 데이터 모델을 활용한 파일럿 연구
신경정신의학
2020 .01
-
치료저항성 주요우울장애 환자의 광치료 증례
신경정신의학
2015 .01
-
한국형 우울장애 약물치료 알고리듬 2021 (VI): 비약물학적 생물치료
신경정신의학
2021 .11
-
한국형 우울장애 약물치료 알고리듬 2017(VII) : 비약물학적 생물치료
우울조울병
2017 .01
-
Times to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive Disorder
PSYCHIATRY INVESTIGATION
2016 .01
-
Evidence-Based Treatment for Depressive Disorder
PSYCHIATRY INVESTIGATION
2015 .01
-
The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) Study: Design and Methodology
PSYCHIATRY INVESTIGATION
2018 .01
-
Contemporary Issues in Depressive Disorders
PSYCHIATRY INVESTIGATION
2019 .01
-
A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
Clinical Psychopharmacology and Neuroscience
2021 .01
-
Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder
Clinical Psychopharmacology and Neuroscience
2018 .01
-
사회불안장애와 공황장애에 동반된 우울증상의 특성 비교
생물정신의학
2015 .01
-
Associations of Serum Serotonin Levels with 12-week and 12-month Remission in Patients with Depressive Disorders
Clinical Psychopharmacology and Neuroscience
2022 .05
-
Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
Clinical Psychopharmacology and Neuroscience
2020 .01
-
한국형 우울장애 약물치료 알고리듬 2021 (IV): 여성 및 노인
신경정신의학
2021 .11
-
주요우울장애 노인 환자의 항우울제 복약이행도 연구
한국임상약학회지
2023 .03
-
항우울제 중단 증후군
신경정신의학
2024 .05
-
Prevalence of Depressive Disorder of Outpatients Visiting Two Primary Care Settings
예방의학회지
2015 .01
-
How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach
Clinical Psychopharmacology and Neuroscience
2020 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2016-513-002070787